Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.
- A Network of Your PeersView more >>
Most Popular Right Now
Dr Richard Michaelson and Kimberly Blackwell, MD discuss their decision-making processes when treating patients with metastatic HR+/HER2- breast cancer. View Now